23 - 26 October
Watch this physician panel and hear Drs Michael Reardon, Rebecca Hahn, Christopher Meduri, and Azeem Latib discuss the design of the DurAVR™ THV and its impact on haemodynamics.
Latest Anteris News
09 Jan 2024
Investor Update Presentation
Anteris is pleased to provide a copy of an Investor Update Presentation to be held today at the Annual J.P. Morgan Healthcare Conference.
21 Nov 2023
Anteris Reports Outstanding 30-Day Haemodynamic Results from the DurAVR™ THV US EFS Trial
Anteris reports 30-day data from the US Early Feasibility Study (EFS) for DurAVR™ Transcatheter Heart Valve (THV). The preliminary results 30 days post-procedure included data from 12 out of the 15 enrolled patients (three patients awaiting scheduling).
Read the full announcement here
Proactive Investors: Anteris Technologies fields "excellent" 30-day haemodynamic results for DurAVR™ THV in US early feasibility study - 21 November 2023
31 Oct 2023
Proactive Interview with Wayne Paterson, CEO of Anteris Technologies
Anteris Technologies CEO Wayne Paterson recently spoke with Proactive Investors about successfully completing enrolment in its FDA approved Early Feasibility Study (EFS or the Study) in the United States for DurAVR™ THV.
26 Oct 2023
Anteris Raises $40 Million In New Equity
Anteris has raised $40 million with the issue of two million new ordinary shares (New Shares) at $20 per New Share (Placement). The funds will be used for preparation for the FDA Pivotal trial of the Company’s DurAVR™ THV for treating severe aortic stenosis, continued Valve-in-Valve trials and general working capital expenses.
25 Oct 2023
Anteris Reports Unprecedented Positive Hemodynamic Results from the Interim Analysis of its US-EFS Trial for DurAVR™ THV
Anteris reports data from its US Early Feasibility Study (EFS) for DurAVR™ Transcatheter Heart Valve (THV), a new class of aortic valve replacement (AVR) and the world’s only biomimetic, single-piece transcatheter aortic valve.
17 Oct 2023
Anteris Completes DurAVR™ THV EFS Enrolment
Anteris reports completing enrolment in its FDA approved Early Feasibility Study (EFS or the Study) in the United States. DurAVR™ THV is a new class of biomimetic valve and the world’s only balloonexpandable, single-piece transcatheter aortic valve. The EFS is an essential step towards receiving FDA clearance in the US for commercialization of this innovative medical technology.
12 Sep 2023
Anteris Announces Participation at the Cantor Healthcare Conference
Anteris Technologies announced today that Wayne Paterson, the Chief Executive Officer of Anteris will present at the Cantor Fitzgerald Annual Global Healthcare Conference in New York, NY on Tuesday, September 26, 2023, at 2:45 p.m. Eastern Time.
12 Sep 2023
Anteris Technologies Named Company of the Year by MedTech Outlook
Anteris Technologies is honored to be named MedTech Outlook’s Company of the Year for 2023. This recognition is a testament to our culture of innovation and the dedication of our team and physician partners to advancing the TAVR field.
14 Aug 2023
DurAVR™ Demonstrates Exceptional Results in Second Valve-in-Valve Case
Anteris reported today that DurAVR™ THV, a new class of biomimetic valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve, was implanted in a second successful Valve-in-Valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP).
09 Aug 2023
Commencement of American Depository Receipt Program
Anteris Technologies Ltd (ASX: AVR) (“Anteris” or the “Company”) announced today that it has established a sponsored Level 1 American Depository Receipt (ADR) program in the United States. The ADR program has been set up to improve U.S. investor access to Anteris ordinary shares.
The ADRs representing Anteris ordinary shares will trade on the over-the-counter (OTC) market with the ticker symbol ANTTY. Deutsche Bank has been appointed as the Depositary Bank for Anteris Technologies’ ADR program.
Business Wire: Anteris Technologies Commences American Depository Receipt Program
09 Aug 2023
Montefiore Enrolls Patients in DurAVR™ THV US Early Feasibility Study
Anteris Technologies Ltd reported today that DurAVR™ Transcatheter Heart Valve (THV), a new class of aortic valve replacement (AVR) and the world’s only biomimetic, single-piece transcatheter aortic valve, was used to successfully treat patients as part of the DurAVR™ THV Early Feasibility Study (EFS or the Study) in the United States. The EFS is an essential step towards receiving FDA approval in the US and commercialisation of this innovative medical technology.
07 Aug 2023
Notice of Extraordinary General Meeting
An Extraordinary General Meeting of Anteris Technologies Ltd will be held will be held via live webcast, and physically at Hilton Brisbane, 190 Elizabeth Street, Brisbane, Queensland 4000, at 10:00 a.m. AEST on Wednesday 6 September 2023.
31 July 2023
Anteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve Procedure
Anteris Technologies Ltd reported today that for the first time, DurAVR™ THV, a new class of biomimetic valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve, was used in a valve-in-valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP).
Watch Proactive Investors Interview
Business Wire: Anteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve Procedure - 1 August 2023
14 June 2023
Anteris CEO Wayne Paterson, discuss the latest DurAVR™ THV Patient Data with Proactive Investors
Latest results show DurAVR™ THV maintained excellent haemodynamic performance at 30 days, as previously reported with this patient cohort at 48 hours post-procedure.
Proactive Investors: Anteris Technologies says latest first-in-human DurAVR™ results are next-level - 14 June 2023
09 June 2023
New Results Show DurAVR™ THV Continues to Demonstrate Sustained Haemodynamics to one year
Anteris Technologies (ASX: AVR) presents the latest data from the DurAVR™ First-In-Human Study at the TVT Conference. Results show DurAVR™ THV continues to maintain excellent haemodynamic performance as previously reported at one year and 30 day time points.
Proactive Investors: Anteris Technologies presents first-in-human data at conference showing "excellent" haemodynamic performance - 09 June 2023
Stockhead: Anteris’ study is progressing well at the one year and 30-day time points - 09 June 2023
31 May 2023
DurAVR™ THV Maintains Exceptional Results in New Patient Cohort
Anteris announces DurAVR™ THV delivers exceptional haemodynamic outcomes in a third patient cohort, comprising seven First-in-Human Study participants and one compassionate case, further validating results previously reported.
29 May 2023
Anteris Technologies Annual General Meeting: Chairman’s Address and Chief Executive Officer Presentation
We are pleased to provide the attached Chairman’s Address and Chief Executive Officer Presentation to the Annual General Meeting.
24 May 2023
Cardiovascular Business: New biomimetic TAVR valve, the first of its kind, linked to strong performance after 1 year
"A new-look transcatheter aortic valve replacement (TAVR) device designed to mimic the patient’s native aortic valve is associated with strong safety outcomes and a “promising hemodynamic performance” after one year, according to new data published in EuroIntervention."
22 May 2023
First in Human Results Presented at EuroPCR with Simultaneous Publication in EuroIntervention
Proactive Investors: Anteris Technologies unveils encouraging FIH results from DurAVR™ heart valve study - 22 May 2023
17 May 2023
Anteris Technologies Granted Additional Utility Patent
Anteris is pleased to announce that the United States Patent and Trademark Office has issued another utility patent to the Company for the novel DurAVR™ transcatheter heart valve (THV).
Stockhead: Anteris issued another utility patent in US - 17 May 2023
19 April 2023
Agreement to Develop New Heart Valve Repair Device
Anteris is pleased to announce that the Company has entered an agreement with v2vmedtech, inc. to partner with leading physicians to develop an innovative heart valve repair device for the minimally invasive treatment of mitral and tricuspid valve regurgitation (“Devices”) – also known as a leaky valve – a market expected to be $4.1 Billion by 2028.
AFR: Anteris Technologies strikes US cardiology deal - 19 April 2023
Stockhead: Anteris to develop innovative heart valve repair device - 19 April 2023
12 April 2023
Anteris Technologies awarded utility patent
The US Patent and Trademark Office has issued a utility patent for the novel transcatheter heart valve replacement technology.
21 Mar 2023
Presentation at NWR Virtual Healthcare Conference
Anteris CEO Wayne Paterson, presents at the NWR Virtual Healthcare Conference on Tuesday 21 March 2023.
15 Feb 2023
Settlement of $35M Capital Raising Transaction
A successful settlement of 1.458 million new ordinary shares in the Company to various sophisticated and professional investors at an issue price of $24.00 per New Share, raising $35 million cash.
09 Feb 2023
FDA Grants Expanded Approval for the DurAVR™ EFS
The United States Food and Drug Administration (FDA) has granted expanded approval for the DurAVR™ THV System in Subjects with Severe Aortic Stenosis: Early Feasibility Study (EFS).
Proactive Investors: Anteris receives FDA expanded approval for DurAVR™ EFS - 9 Feb 2023
06 Feb 2023
Proposed $50 Million Capital Facility
Anteris is pleased to announce that the Company has entered into a non-binding agreement with Yorkville Advisors Global, LP (Investor) to provide a $50 million SEPA facility to Anteris.
16 Jan 2023
DurAVR™ First in Human Study 12 Month Results
Proactive Investors: Anteris delivers strong 12-month results from DurAVR™ FIH study - 16 Jan 2023
06 Dec 2022
Anteris hails FDA early feasibility study approval for DurAVR™
CEO Wayne Paterson discusses with Proactive the news that the USA FDA has conditionally approved the DurAVR™ (THV) system for investigational device exemption (IDE) application to kick off an early feasibility study (EFS). The study will evaluate the safety and feasibility of the DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.
28 Nov 2022
FDA approves Early Feasibility Study for the DurAVR™ THV System
Anteris is pleased to announce the U.S. Food and Drug Administration (FDA) has conditionally approved the DurAVR™ Transcatheter Heart Valve (THV) System for investigational device exemption (IDE) application to commence an Early Feasibility Study (EFS).
09 Nov 2022
Anteris Technologies receives exciting acknowledgment as a "Top 10 MedTech Startup 2022" by industry publication MedTech Outlook.
09 Nov 2022
CEO Magazine - Spotting Opportunities
When CEO and Managing Director Wayne Paterson joined Anteris Technologies he took the opportunity to shift the focus from competing in a A$50 Million sector to entering a A$15 Billion Industry
28 Sep 2022
Anteris has valve world talking about 'human-like characteristics' of DurAVR™
Anteris' CEO Wayne Paterson speaks with Proactive about its productive presentation at the annual TCT medical conference, the world’s largest interventional cardiology conference. 30-Day clinical data was presented for its full cohort of 13 patients implanted with DurAVR™ THV during its First-In-Human trial. It compared the results with outcomes of its most recent 22 patient study, which showed DurAVR™ THV technology performed favourably against other transcatheter aortic valve replacements and surgical aortic valve replacements at six months.
19 Sep 2022
Results Demonstrating Restoration of Normal Pre-Disease Flow
Anteris presents preliminary results demonstrating for the first-time restoration of normal pre-disease blood flow after aortic valve replacement at (TCT) conference, the world's foremost meeting of interventional cardiologists. In a study of 22 patients comparing valve flow amongst current aortic valve replacement technologies, Anteris demonstrated no significant difference to the normal healthy aortic valve’s flow with DurAVR™ THV. When current generation TAVR (transcatheter aortic valve replacement) and SAVR (surgical aortic valve replacement) valves were compared to the healthy aortic valve,both groups demonstrated statistically significant worse flow.
11 Jul 2022
Update on First In Human DurAVR™ THV Study
Anteris reports the 30-day follow-up results on the second cohort of (eight) patients showed clinically significant improvements.
21 Jun 2022
DurAVR™ First In Human Patient 6 Month Study Follow Up
Anteris is pleased to announce the 6 month follow up of our first cohort of 5 patients. The 6 month follow up is informal (formal follow ups according to the study protocol are 30 days and 1 year). All patients are doing very well and in fact have shown marked improvements since the 3 month follow up.
06 Jun 2022
Local Australian News, Channel 9, interview and cover Anteris at our Malaga Facility.
06 Jun 2022
06 Jun 2022
Anteris CEO Wayne Paterson interviews the implanting physicians from the DurAVR™ First-in-Human Study
2 Mar 2022
Investment of 20 Million into Anteris
We are pleased to announce Perceptive Life Sciences has invested USD 20 million into Anteris
25 Jan 2022
Anteris Technologies' 30-day data
30-day data released from in-human heart valve trial yields promising results
24 Jan 2022
Anteris Reports Successful Interim Results for the First-in-Human Trial for DurAVR
25 Nov 2021
The Science behind a Valve Designed for Life - Dr Christopher Meduri
An Expert Interview with Dr C. Meduri from Karolinska University Hospital (Stockholm – SE) where he discusses the “The Science Behind a Valve Designed for Life” at PCR London Valves 2021
25 Nov 2021
Anteris' CEO talks 'outstanding results'
Anteris Technologies CEO talks 'outstanding results' from first human DurAVR patients with Proactive Investors
Previous Anteris Interviews
16 - 19 May 2023
Watch this physician panel and hear Drs Christopher Meduri, Susheel Kodali, and João Cavalcante discuss early safety and feasibility of the first-in-class biomimetic transcatheter aortic valve – DurAVR™ THV.
28 November 2022
PCR London Valves 2022 - Panel Discussion
A panel discussion on the formal results of a comparative study which investigated aortic flow physiology by cardiac MRI (cMRI) in five patients who received a DurAVR™ transcatheter aortic valve (first-in-human). The study compared DurAVR™ to normal age-height-weight matched controls, other transcatheter aortic valve implants (TAVI) and patients who had surgical aortic valve replacement (SAVR).
30 September 2022
TCT MD 2022 - Panel Discussion
Anteris presents detailed results of the 30-day outcomes for the combined cohort of 13 patients, from the DurAVR™ THV First-In-Human (FIH) trial at the world’s premier meeting for interventional cardiovascular medicine.
May 2022
Anteris crosses live to the Cath Lab
Anteris Technologies CEO, Wayne Paterson is Live in the Cath Lab.
Previous Anteris Presentations
27 - 30 Oct 2024
Dr. Amar Krishnaswamy presented the latest MRI data analysis demonstrating restoration of healthy laminar flow with DurAVR® THV and the impact on the left ventricle at TCT 2024.
05 - 07 June 2024
See the latest update on the DurAVR™ FIH Study. Dr. João Cavalcante presents findings showcasing the flow and haemodynamics that lead to significant LV mass regression at New York Valves 2024.
05 - 07 June 2024
See the latest update on Valve-in-Valve procedures in patients with DurAVR™ THV and the restoration of haemodynamics, presented by Dr. Anita Asgar at New York Valves 2024.
14 - 17 May 2024
Discover the latest update on the DurAVR™ US Early Feasibility Study (EFS) & First-in-Human (FIH) Data Update. Dr. Christopher Meduri presented 30-day data for all 15 enrolled DurAVR™ THV EFS patients at the EuroPCR conference in May 2024.
19-21 Nov 2023
See the Early Feasibility Study (EFS) data presented at PCR London Valves 2023, showing excellent sustained haemodynamic performance at 30 days post-implantation.
23-26 Oct 2023
See the Early Feasibility Study (EFS) discharge data presented at TCT 2023, showing remarkable haemodynamic performance.
23 - 26 Oct 2023
See the latest First-in-Human (FIH) Study data presented at TCT 2023, showing sustained mean haemodynamic performance from all 20 patients at 6 months post-procedure.
9 June 2023
See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.
16 - 19 May 2023
EuroPCR 2023 DurAVR™ 1 Year Data
View the 1-year Data from the DurAVR™ THV First-In-Human Study presented at EuroPCR 2023 by Dr. Susheel Kodali. Excellent haemodynamic results are sustained to 1 year.
November 2022
PCR London Valves 2022 - Late Breaking Clinical Trial
DurAVR™ Transcatheter Aortic Valve First-in-Human Study: Impact of Novel Leaflet Design
Presented by: Christopher U. Meduri, MD MPH
PCR London Valves 2022 - A Comparative Study
DurAVR™ TAVI novel leaflet design restores ascending aortic flow haemodynamics on cardiac MRI: First-in-human study